A detailed history of Credit Suisse Ag transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 117,399 shares of CPRX stock, worth $1.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
117,399
Previous 108,540 8.16%
Holding current value
$1.8 Million
Previous $1.82 Million 2.58%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$13.18 - $17.11 $116,761 - $151,577
8,859 Added 8.16%
117,399 $1.87 Million
Q4 2023

Feb 08, 2024

BUY
$11.78 - $17.29 $5,136 - $7,538
436 Added 0.4%
108,540 $1.82 Million
Q3 2023

Nov 13, 2023

SELL
$11.69 - $15.02 $394,233 - $506,534
-33,724 Reduced 23.78%
108,104 $1.26 Million
Q2 2023

Aug 11, 2023

BUY
$11.5 - $18.08 $646,622 - $1.02 Million
56,228 Added 65.69%
141,828 $1.91 Million
Q1 2023

May 10, 2023

BUY
$14.34 - $21.05 $33,684 - $49,446
2,349 Added 2.82%
85,600 $1.42 Million
Q4 2022

Feb 13, 2023

BUY
$12.25 - $19.5 $22,111 - $35,197
1,805 Added 2.22%
83,251 $1.55 Million
Q3 2022

Nov 10, 2022

BUY
$7.06 - $15.52 $85,694 - $188,381
12,138 Added 17.51%
81,446 $1.05 Million
Q2 2022

Aug 12, 2022

SELL
$6.23 - $8.57 $17,986 - $24,741
-2,887 Reduced 4.0%
69,308 $486,000
Q1 2022

May 16, 2022

SELL
$5.31 - $8.31 $9,966 - $15,597
-1,877 Reduced 2.53%
72,195 $598,000
Q4 2021

Feb 14, 2022

BUY
$5.21 - $7.45 $15,874 - $22,700
3,047 Added 4.29%
74,072 $501,000
Q3 2021

Nov 12, 2021

BUY
$4.85 - $6.04 $33,309 - $41,482
6,868 Added 10.7%
71,025 $376,000
Q2 2021

Aug 16, 2021

SELL
$4.29 - $6.05 $96,443 - $136,010
-22,481 Reduced 25.95%
64,157 $369,000
Q1 2021

May 14, 2021

SELL
$3.45 - $4.69 $368,825 - $501,389
-106,906 Reduced 55.24%
86,638 $399,000
Q4 2020

Feb 12, 2021

SELL
$2.97 - $3.83 $334,329 - $431,139
-112,569 Reduced 36.77%
193,544 $646,000
Q3 2020

Nov 13, 2020

BUY
$2.97 - $5.08 $31,125 - $53,238
10,480 Added 3.54%
306,113 $910,000
Q2 2020

Aug 12, 2020

SELL
$3.48 - $5.05 $84,657 - $122,851
-24,327 Reduced 7.6%
295,633 $1.37 Million
Q1 2020

May 13, 2020

SELL
$2.61 - $5.21 $631,914 - $1.26 Million
-242,113 Reduced 43.08%
319,960 $1.23 Million
Q4 2019

Feb 12, 2020

BUY
$3.67 - $5.7 $1.86 Million - $2.88 Million
505,667 Added 896.48%
562,073 $2.11 Million
Q3 2019

Nov 12, 2019

BUY
$3.89 - $7.43 $34,469 - $65,837
8,861 Added 18.64%
56,406 $300,000
Q2 2019

Aug 14, 2019

BUY
$2.7 - $6.11 $70,688 - $159,965
26,181 Added 122.55%
47,545 $182,000
Q1 2019

May 14, 2019

BUY
$2.11 - $5.33 $13,430 - $33,925
6,365 Added 42.44%
21,364 $110,000
Q4 2018

Feb 13, 2019

BUY
$1.92 - $3.62 $28,798 - $54,296
14,999 New
14,999 $29,000
Q3 2018

Nov 13, 2018

SELL
$2.81 - $3.78 $70,384 - $94,681
-25,048 Closed
0 $0
Q2 2018

Aug 14, 2018

SELL
$2.26 - $3.84 $13,639 - $23,174
-6,035 Reduced 19.42%
25,048 $78,000
Q1 2018

May 15, 2018

BUY
$2.39 - $4.01 $22,599 - $37,918
9,456 Added 43.72%
31,083 $75,000
Q4 2017

Feb 14, 2018

SELL
$2.51 - $4.4 $65,453 - $114,738
-26,077 Reduced 54.66%
21,627 $84,000
Q3 2017

Nov 14, 2017

BUY
$2.4 - $2.94 $80,940 - $99,151
33,725 Added 241.25%
47,704 $120,000
Q2 2017

Aug 14, 2017

BUY
N/A
13,979
13,979 $38,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $1.57B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.